Vitamin D replacement for cirrhosis-related bone disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 12, 2006, Pages 689-699

  Crawford, Bronwyn A ^a,b   Labio, Eternity D ^f   Strasser, Simone I ^c   McCaughan, Geoffrey W ^d,e  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b University of Sydney   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Gastroenterology and Liver Services   (Australia)

^f UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; STEROID; VITAMIN D; VITAMIN D BINDING PROTEIN; ZOLEDRONIC ACID;

BLEEDING; BONE DENSITY; BONE DISEASE; CALCIUM INTAKE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HEALTH CARE AVAILABILITY; HEART FAILURE; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOCALCEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; OPTIMAL DRUG DOSE; OSTEOMALACIA; OSTEOPOROSIS; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SEIZURE; SKIN BRUISING; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

DIPHOSPHONATES; HUMANS; LIVER CIRRHOSIS; OSTEOPOROSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 35248836743     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0637     Document Type: Review

References (89)

1. Leslie W et al. (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125: 941-966
2. Diamond T et al. (1989) Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 69: 1234-1239
3. Collier J et al. (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50 (Suppl 1): I1-i9
4. Crawford B et al. (2003) The heterogeneity of bone disease in cirrhosis: a multivariate analysis. Osteoporosis Int 14: 987-994
5. American Gastroenterological Association (2003) American Gastroenterological Association medical position statement: Osteoporosis in hepatic disorders. Gastroenterology 125: 937-940
6. McCaughan G and Feller R (1994) Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 12: 223-231
7. Hay J (1995) Bone disease in cholestatic liver disease. Gastroenterology 108: 276-283
8. Rouillard S and Lane N (2001) Hepatic osteodystrophy. Hepatology 33: 301-307
9. Hay J (2003) Osteoporosis in liver diseases and after liver transplantation. J Hepatol 38: 856-865
10. Working Group of the Australian and New Zealand Bone and Mineral Society Endocrine Society of Australia and Osteoporosis Australia (2005) Vitamin D and adult bone health in Australia and New Zealand: A position statement. Med J Aust 182: 281-285
11. Samanek A et al. (2006) Estimates of beneficial and harmful sun exposure times during the year for major Australian population centres. Med J Aust 184: 338-341
12. Bikle D et al. (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63: 954-959
13. 3 in healthy adults. J Clin Endocrinol Metab 46: 756-765
14. Binkley N et al. (2004) Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. J Clin Endocrinol Metab 89: 3152-3157
15. Hollis B (2004) The determination of circulating 25-hydroxyvitamin D: No easy task [editorial]. J Clin Endocrinol Metab 89: 3149-3151
16. Carmeliet G et al. (1999) The vitamin D hormone and its nuclear receptor: Genomic mechanisms involved in bone biology. In Dynamics of Bone and Cartilage Metabolism (eds Seibel M et al.) San Diego: Academic Press
17. Compston J (1986) Hepatic osteodystrophy: Vitamin D metabolism in patients with liver disease. Gut 27: 1073-1090
18. Barragry J et al. (1978) Plasma vitamin D-binding globulin in vitamin D deficiency, pregnancy and chronic liver disease. Clin Chim Acta 87: 359-365
19. Bikle D et al. (1986) Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Invest 78: 748-752
20. Masuda S et al. (1989) Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 35: 225-234
21. Jung R et al. (1978) Abnormal vitamin D metabolism in cirrhosis. Gut 19: 290-293
22. White P and Cooke N (2000) The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 11: 320-327
23. Dibble J et al. (1984) A survey of vitamin D deficiency in gastroenterological and liver disorders. Q J Med 209: 119-134
24. Sahota O et al. (1999) Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hips in patients with established osteoporosis. Clin Endocrinol 51: 217-221
25. Meunier P (2001) Vitamin D insufficiency: Reappraisal of its definition threshold and bone consequences. In Nutritional Aspects of Osteoporosis, 167-172 (eds Burckhardt P et al.) San Diego: Academic Press
26. Vieth R et al. (2003) Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88: 185-191
27. Wills M and Savory J (1984) Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci 14: 189-197
28. Heaf J (1985) Hepatic osteodystrophy. Scand J Gastroenterol 20: 1035-1040
29. 3 treatment. Gastroenterology 83: 97-102
30. Skinner R et al. (1977) 25-hydroxylation of vitamin D in primary biliary cirrhosis. Lancet 1: 720-721
31. Mawer E et al. (1985) Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci (Lond) 69: 561-570
32. 3. Dig Dis Sci 28: 145-153
33. Plourde V et al. (1988) Severe cholestasis leads to vitamin D depletion without perturbing its C-25 hydroxylation in the dog. Hepatology 8: 1577-1585
34. 3 in micronodular cirrhosis: A structure-function study in the rat. J Bone Miner Res 3: 461-471
35. Goldsmith R (1982) Enterohepatic cycling of vitamin D and its metabolites. Miner Electrolyte Metab 8: 289-292
36. Fraser D (1983) The physiological economy of vitamin D. Lancet 1: 969-971
37. Compston J and Ledger J (1983) Vitamin D. Lancet 2: 45-46
38. Clements M et al. (1984) Enterohepatic circulation of vitamin D: A reappraisal of the hypothesis. Lancet 1: 1376-1379
39. 3 following chronic ethanol administration in the rat. Life Sci 28: 279-286
40. Davies M et al. (1997) Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25 dihydroxyvitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab 82: 209-212
41. Clements M et al. (1987) A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 325: 62-65
42. Chen C et al. (1996) Metabolic bone disease of liver cirrhosis: Is it a parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 11: 417-421
43. Sahota O et al. (2004) The relationship between vitamin D and parathyroid hormone: Calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35: 312-319
44. Dibble J et al. (1981) Evidence for secondary hyperparathyroidism in the osteomalacia associated with chronic liver disease. Clin Endocrinol 15: 373-383
45. Crippin J et al. (1994) Hepatic osteodystrophy in primary biliary cirrhosis: Effects of medical treatment. Am J Gastroenterol 89: 47-50
46. Herlong H et al. (1982) Bone disease in primary biliary cirrhosis: histological features and response to 25-hydroxyvitamin D. Gastroenterology 83: 103-108
47. Reed J et al. (1980) Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 78: 512-517
48. Compston J et al. (1980) Vitamin D prophylaxis and osteomalacia in chronic cholestatic liver disease. Dig Dis Sci 25: 28-32
49. 2, 25-hydroxyvitamin D, or supportive treatment. Hepatology 4: 266-273
50. Shiomi S et al. (1999) Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 14: 547-552
51. Floreani A et al. (1997) A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 24: 239-244
52. Tilyard M et al. (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357-362
53. Neer R et al. (1992) Calcitriol or calcium for postmenopasual osteoporosis [letter]. N Engl J Med 327: 284
54. Ebeling P et al. (2001) Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind placebo study. J Clin Endocrinol Metab 86: 4098-4103
55. Kalef-Ezra J et al. (1996) Amount and composition of bone minerals in chronic liver disease. Dig Dis Sci 41: 1008-1013
56. Bonkovsky H et al. (1990) Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 12: 273-280
57. Sahota O et al. (2006) Vitamin D insufficiency and the blunted PTH response in established osteoporosis: The role of magnesium deficiency. Osteoporosis Int 17: 1013-1021
58. Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22: 477-501
59. Souberbielle J-C et al. (2001) Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86: 3086-3090
60. Sambrook P et al. (2004) Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxyvitamin D status, bone mass, and renal function in the frail and very old: A cohort study. J Clin Endocrinol Metab 89: 5477-5481
61. McKenna M and Freaney R (1998) Secondary hyperparathyroidism in the elderly: Means to define hypovitaminosis D. Osteoporosis Int 8 (Suppl 2): S3-S6
62. Steingrimsdottir L et al. (2005) Relationship between serum parathyroid hormone levels, vitamin D sufficiency and calcium intake. JAMA 294: 2336-2341
63. 2+ sensing receptor. Proc Natl Acad Sci USA 97: 4814-4819
64. Papadimitropoulos E et al. (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23: 560-569
65. Bischoff-Ferrari H et al. (2005) Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293: 2257-2264
66. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D): A randomised placebo-controlled trial. Lancet 365: 1621-1628
67. Cooper L et al. (2003) Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr 77: 1324-1329
68. Reis A et al. (2005) Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab 31: 318-325
69. Holick M (2005) Vitamin D: Important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune disease, and some cancers. South Med J 98: 1024-1027
70. Holick M (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clinic Proc 81: 353-373
71. Liu S et al. (2005) Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 28: 2926-2932
72. Forman J et al. (2005) Vitamin D intake and the risk of incident hypertension. Hypertension 46: 676-682
73. Black P and Scragg R (2005) Relationship between 25-hydroxyvitamin D and pulmonary function in the third national health and nutritional examination survey. Chest 128: 3792-3798
74. Schleithoff S et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83: 754-759
75. Garland C et al. (2006) The role of vitamin D in cancer prevention. Am J Public Health 96: 252-261
76. Grant W (2006) Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J Natl Med Assoc 98: 357-364
77. Pfeifer M et al. (2002) Vitamin D and muscle function. Osteoporosis Int 13: 187-194
78. Gerdhem P et al. (2005) Association between 25-hydroxyvitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporosis Int 16: 1425-1431
79. Staud R (2005) Vitamin D: More than just affecting calcium and bone. Curr Rheumatol Rep 7: 356-364
80. Teoh N and Farrell G (2004) Management of chronic hepatitis C virus infection: A new era of disease control. Intern Med J 34: 324-337
81. 2. Am J Clin Nutr 68: 854-858
82. 3 in humans. J Clin Endocrinol Metab 89: 5387-5391
83. 3. Scand J Clin Lab Invest 46: 785-790
84. Diamond T et al. (2005) Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: Efficacy and safety data. Med J Aust 183: 10-12
85. Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev 23: 496-507
86. Sambrook P (2005) How to prevent steroid-induced osteoporosis. Ann Rheum Dis 64: 176-178
87. Crawford B et al. (2006) Zoledronic acid prevents bone loss following liver transplantation - a randomised, placebo-controlled trial. Ann Intern Med 144: 239-248
88. MacIsaac R et al. (2002) Seizures after alendronate. J R Soc Med 95: 615-616
89. Van Staa T et al. (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 1001-1005